Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of K(ATP)-channels

European Journal of Pharmacology

Volumn 367, Issue 1, 1999, Pages 33-39

  Zacharowski, Kai ^a   Olbrich, Antje ^a   Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

(Rat); E type; EP receptor; K+ channel blocker; Myocardial ischaemia; Prostaglandin; Protein kinase C; Reperfusion; TEI 3356

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM); CHELERYTHRINE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; TEI 3356; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ADENOSINE TRIPHOSPHATE; ALKALOIDS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZOPHENANTHRIDINES; DECANOIC ACIDS; ENZYME INHIBITORS; EPOPROSTENOL; HEMODYNAMIC PROCESSES; HYDROXY ACIDS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PHENANTHRIDINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN E; STAUROSPORINE;

EID: 0032966016     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00963-7     Document Type: Article

References (32)

1. Baller D., Bretschneider H.J., Hellige G. A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res. Cardiol. 76:1981;163-181.
2. Coker S.J., Parratt J.R. Prostacyclin-antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J. Cardiovasc. Pharmacol. 5:1983;557-567.
3. Coleman, R.A., Kennedy, I., Humphrey, P.P.A., Brunce, K., Lumley, P., 1990. Comprehensive Medicinal Chemistry. In: Hansch, C., Samnes, P.G., Taylor, J.B., Emmet, J.C. (Eds.), Pergamon, Oxford, pp. 643.
4. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
5. Downey J.M., Cohen M.V. Signal transduction in ischemic preconditioning. Z. Kardiol. 84:1995;77-86.
6. Garlid K.D., Paucek P., Yarov-Yarovoy V., Sun X., Schindler P.A. The mitochondrial KATP channel as a receptor for potassium channel openers. J. Biol. Chem. 271:1996;8796-8799.
7. + channels. Possible mechanism of cardioprotection. Circ. Res. 81:1997;1072-1082.
8. Hide E.J., Thiemermann C. Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br. J. Pharmacol. 118:1996;1409-1414.
9. Hide E.J., Ney P., Piper J., Thiemermann C., Vane J.R. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br. J. Pharmacol. 116:1995;2435-2440.
10. Hohlfeld T. Regulation of prostaglandin receptors in myocardial ischemia. Agents Actions. 45:1995;33-37. Suppl.
11. Hohlfeld T., Zucker T.P., Meyer J., Schror K. Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonischemic and ischemic pig heart. Circ. Res. 81:1997;765-773.
12. Hutton I., Parratt J.R., Lawrie T.D. Cardiovascular effects of prostaglandin E1 in experimental myocardial infarction. Cardiovasc. Res. 7:1973;149-155.
13. Jenkins D.P., Kerac M., Yellon D.M. Its role in ischemic preconditioning: protein kinase C and the KATP channel in isolated rat heart. J. Mol. Cell. Cardiol. 27:1995;A154.
14. Jugdutt B.I., Hutchins G.M., Bulkley B.H., Becker L.C. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ. Res. 49:1981;685-700.
15. Kaye A.D., Nossaman B.D., Ibrahim I.N., Feng C.J., Kadowitz P.J. Influence of protein kinase C inhibitors on vasoconstrictor responses in the pulmonary vascular bed of cat and rat. Am. J. Physiol. 268:1995;L532-538.
16. Kozak W., Klir J.J., Conn C.A., Kluger M.J. Attenuation of lipopolysaccharide fever in rats by protein kinase C inhibitors. Am. J. Physiol. 273:1997;R873-879.
17. + channels. A possible mechanistic link to ischemic preconditioning. Circ. Res. 79:1996;399-406.
18. Liu Y., Ytrehus K., Downey J.M. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J. Mol. Cell. Cardiol. 26:1994;661-668.
19. Lucchesi B.R., Mullane K.M. Leukocytes and ischemia-induced myocardial injury. Annu. Rev. Pharmacol. Toxicol. 26:1986;201-224.
20. Negishi M., Harazono A., Sugimoto Y., Hazato A., Kurozumi S., Ichikawa A. TEI-3356, a highly selective agonist for the prostaglandin EP3 receptor. Prostaglandins. 48:1994;275-283.
21. Nichols C.G., Lederer W.J. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am. J. Physiol. 261:1991;H1675-1686.
22. Parratt J.R. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol. Sci. 15:1994;19-25. published erratum appears in Trends Pharmacol Sci 1994 Feb; 15 (2):39.
23. Parratt J.R., Kane K.A. KATP channels in ischaemic preconditioning. Cardiovasc. Res. 28:1994;783-787.
24. Paucek P., Yarov-Yarovoy V., Sun X., Garlid K.D. Physiological and pharmacological activators of mitochondrial KATP channel. Biophys. 68:1995;A145.
25. Schrör K. Eicosanoids and myocardial ischaemia. Basic Res. Cardiol. 82:1987;235-243.
26. Schrör K., Thiemermann C., Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation. Naunyn Schmiedeberg's Arch. Pharmacol. 338:1988;268-274.
27. Simpson P.J., Mickelson J., Fantone J.C., Gallagher K.P., Lucchesi B.R. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J. Pharmacol. Exp. Ther. 244:1988;619-624.
28. Speechly-Dick M.E., Mocanu M.M., Yellon D.M. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ. Res. 75:1994;586-590.
29. + channel. Prog. Neurobiol. 41:1993;21-30.
30. Yoshida K., Kawamura S., Mizukami Y., Kitakaze M. Implication of protein kinase C-alpha, delta, and epsilon isoforms in ischemic preconditioning in perfused rat hearts. J. Biochem. (Tokyo). 122:1997;506-511.
31. Ytrehus K., Liu Y., Downey J.M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 266:1994;H1145-1152.
32. Zijlstra W.G., Brunsting J.R., Hoor F.t., Vergroesen A.J. Prostaglandin E 1 and cardiac arrhythmia. Eur. J. Pharmacol. 18:1972;392-395.